News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,899 Results
Type
Article (41357)
Company Profile (263)
Press Release (689263)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204850)
Career Advice (2032)
Deals (35584)
Drug Delivery (129)
Drug Development (81518)
Employer Resources (173)
FDA (16511)
Job Trends (14982)
News (346837)
Policy (32751)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2595)
Accelerated approval (47)
Adcomms (26)
Allergies (171)
Alliances (49582)
ALS (210)
Alzheimer's disease (1796)
Antibody-drug conjugate (ADC) (446)
Approvals (16898)
Artificial intelligence (661)
Autoimmune disease (292)
Automation (56)
Bankruptcy (362)
Best Places to Work (11635)
BIOSECURE Act (20)
Biosimilars (222)
Biotechnology (170)
Bladder cancer (194)
Brain cancer (71)
Breast cancer (751)
Cancer (5818)
Cardiovascular disease (470)
Career advice (1724)
Career pathing (42)
CAR-T (331)
CDC (56)
Celiac Disease (3)
Cell therapy (898)
Cervical cancer (47)
Clinical research (70836)
Collaboration (2053)
Company closure (5)
Compensation (1403)
Complete response letters (80)
COVID-19 (2742)
CRISPR (108)
C-suite (1122)
Cystic fibrosis (152)
Data (7908)
Decentralized trials (3)
Denatured (27)
Depression (161)
Dermatology (86)
Diabetes (586)
Diagnostics (6927)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (316)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (283)
Earnings (92113)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119522)
Executive appointments (1081)
FDA (20240)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (18)
Frontotemporal dementia (34)
Funding (1723)
Gene editing (234)
Generative AI (56)
Gene therapy (722)
GLP-1 (1054)
Government (4731)
Grass and pollen (6)
Guidances (408)
Healthcare (18998)
HIV (79)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (288)
Immuno-oncology (93)
Indications (194)
Infectious disease (3080)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (290)
Interviews (319)
IPO (16667)
IRA (50)
Job creations (3647)
Job search strategy (1430)
JPM (58)
Kidney cancer (19)
Labor market (100)
Layoffs (562)
Leadership (39)
Legal (7953)
Liver cancer (100)
Longevity (32)
Lung cancer (764)
Lymphoma (429)
Machine learning (60)
Management (59)
Manufacturing (1047)
MASH (186)
Medical device (13931)
Medtech (14054)
Mergers & acquisitions (20165)
Metabolic disorders (1498)
mRNA (204)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (414)
Neuropsychiatric disorders (105)
Neuroscience (3300)
Neurotech (1)
NextGen: Class of 2026 (6520)
Non-profit (4530)
Now hiring (78)
Obesity (701)
Opinion (288)
Ovarian cancer (220)
Pain (255)
Pancreatic cancer (303)
Parkinson's disease (360)
Partnered (33)
Patents (594)
Patient recruitment (671)
Peanut (62)
People (59588)
Pharmaceutical (58)
Pharmacy benefit managers (32)
Phase 1 (22080)
Phase 2 (31209)
Phase 3 (23218)
Pipeline (8768)
Policy (317)
Postmarket research (2569)
Preclinical (9413)
Press Release (64)
Prostate cancer (304)
Psychedelics (54)
Radiopharmaceuticals (323)
Rare diseases (1075)
Real estate (5970)
Recruiting (70)
Regulatory (25405)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (39)
RNA editing (22)
RSV (88)
Schizophrenia (176)
Series A (288)
Series B (213)
Service/supplier (11)
Sickle cell disease (112)
Special edition (24)
Spinal muscular atrophy (166)
Sponsored (48)
Startups (3640)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1090)
Venture capital (108)
Weight loss (450)
Women's health (128)
Worklife (20)
Date
Today (154)
Last 7 days (856)
Last 30 days (3533)
Last 365 days (30175)
2026 (12623)
2025 (30171)
2024 (35208)
2023 (40072)
2022 (51173)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35015)
2017 (32107)
2016 (31479)
2015 (37553)
2014 (31327)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27330)
Location
Africa (741)
Alabama (93)
Alaska (7)
Arizona (348)
Arkansas (14)
Asia (39678)
Australia (6507)
California (13288)
Canada (3765)
China (1340)
Colorado (567)
Connecticut (579)
Delaware (407)
Europe (85881)
Florida (1988)
Georgia (426)
Hawaii (3)
Idaho (62)
Illinois (1050)
India (90)
Indiana (601)
Iowa (23)
Japan (539)
Kansas (131)
Kentucky (50)
Louisiana (40)
Maine (76)
Maryland (1592)
Massachusetts (9473)
Michigan (364)
Minnesota (717)
Mississippi (6)
Missouri (144)
Montana (33)
Nebraska (29)
Nevada (143)
New Hampshire (84)
New Jersey (3495)
New Mexico (29)
New York (3475)
North Carolina (1686)
North Dakota (9)
Northern California (6662)
Ohio (397)
Oklahoma (23)
Oregon (41)
Pennsylvania (2676)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (86)
South Dakota (2)
Southern California (5245)
Tennessee (211)
Texas (2112)
United States (46857)
Utah (394)
Vermont (1)
Virginia (321)
Washington D.C. (80)
Washington State (1061)
West Virginia (4)
Wisconsin (125)
Wyoming (2)
730,899 Results for "agendia inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress
April 30, 2026
·
3 min read
Press Releases
Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer
May 4, 2026
·
4 min read
Press Releases
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer
January 20, 2026
·
4 min read
Press Releases
Agendia to Showcase MammaPrint and BluePrint Utility in Guiding Anthracycline Therapy at the 2025 San Antonio Breast Cancer Symposium
November 26, 2025
·
5 min read
Press Releases
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium
November 5, 2025
·
3 min read
Press Releases
Agendia, Inc. Provides Review of Successful 2024
January 9, 2025
·
7 min read
Biotech Beach
Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®
Agendia®, Inc., announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.
February 1, 2024
·
4 min read
Biotech Beach
Agendia to Unveil Robust Suite of Data at 2024 ASCO to Further Advance Breast Cancer Care
Agendia®, Inc., announced that new data on its comprehensive genomic tests will be presented at the American Society of Clinical Oncology Annual Meeting, taking place May 31st – June 4th, 2024, in Chicago, Illinois.
May 24, 2024
·
5 min read
Press Releases
Agendia to Present FLEX Study Data on Impact of BluePrint® at ESMO Breast Cancer 2025
May 6, 2025
·
4 min read
Biotech Beach
Agendia to Present New Data on 3-Year Outcome of Chemotherapy Treatment in Patients with Early-Stage Breast Cancer at 2024 ASCO
Agendia ® , Inc. today announced it will present new data on the 3-year outcome of patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer when treated with two different chemotherapy regimens.
May 31, 2024
·
5 min read
1 of 73,090
Next
